FeesSafety
Pluang+

Nexxen and Brainlabs drive 8.1M+ impressions with Smart TV ads during global soccer event in Canada

Market News
23 Oct 2026
GlobeNewsWire
View Source
Bullish
Nexxen and Brainlabs drive 8.1M+ impressions with Smart TV ads during global soccer event in Canada

Nexxen and Brainlabs executed a Smart TV home screen advertising campaign for a global retailer in Canada, generating over 8.1 million impressions and reaching more than 516,000 unique viewers during an international soccer tournament. The campaign used exclusive placements on Hisense Smart TVs to capture audience attention right as they turned on their TVs, boosting brand visibility at a key sporting event. This approach highlights the potential of home screen ads to engage viewers before content starts, offering brands a new way to build awareness during major events. Brainlabs plans to continue using this format for future high-profile campaigns.

Nexxen and Brainlabs' Smart TV advertising campaign is the subject, providing context for media sector activity. For readers following Media-sector US stocks on Pluang, here is the market snapshot as of Oct 23, 2026 18:02 WIB: out of 58 stocks, 15 rose and 39 fell. Notable movers include MTCH at USD 45.42 with 0% Sell / 100% Buy order activity, CHTR at USD 110.59 with 72% Sell / 28% Buy, and LUMN at USD 4.42 with 11% Sell / 89% Buy.

More News

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App